INTRODUCTION
============

The use of dermal regeneration templates was first described by Burke et al^[@R1]^ in 1981. In its commercial form, the most widely used dermal regeneration template is Integra (Integra LifeScience Corporation, Plainsboro, N.J.), which is a bilayer composed of a matrix of bovine collagen cross-linked with glycosaminoglycans from shark chondroitin sulfate with an overlying protective silicone layer.^[@R2]^ The use of Integra templates in reconstructive surgery has been described in burns,^[@R1],[@R3]--[@R5]^ scalp,^[@R6],[@R7]^ limbs,^[@R8]^ abdominal wall,^[@R9]^ degloving injuries,^[@R10]^ keloids and hypertrophic scars,^[@R11]^ purpura fulminans,^[@R12]^ hypospadias,^[@R13]^ diabetic foot ulcers,^[@R14]^ and necrotizing soft-tissue infections^[@R15]^ among other uses.

Although Integra has been shown to be an effective reconstructive tool with excellent functional outcomes, aesthetic results, and high rates of long-term engraftment,^[@R3]--[@R5]^ several complications may be associated with its use. The most common complications linked to Integra use are infections.^[@R5],[@R16]--[@R18]^ Most of the time, these infections are superficial, are associated with a lower rate of graft take, and can be resolved with antibiotics and negative-pressure therapy.^[@R5],[@R19]^ In this article, we present the results of an extensive literature review of studies reporting infectious complications associated with Integra-based wound closure.

METHODS
=======

We conducted a comprehensive literature search to identify previous articles by indexing PubMed and Ovid. We used these search terms: (\[Integra OR (dermal regenerative matrix) OR (dermal regeneration matrix) OR (dermal regenerative template) OR (dermal regeneration template) OR (dermal substitute) OR (skin substitute) OR (artificial skin)\] AND skin) AND infection, which generated 3508 articles for initial review.

Eligibility for Inclusion
-------------------------

The article selection criteria were peer-reviewed publications, case reports or case series utilizing Integra for wound repair, and articles reporting infection rate as one of the surgical outcomes. If the data used in one published article had been reported in another study, we included only the article with the most complete and recent data set. Figure [1](#F1){ref-type="fig"} is a diagram showing the steps we followed to identify and select articles for this literature review.

![Steps taken to perform the literature review to identify articles who report cases of infections as postoperative outcomes following skin reconstruction with Integra.](gox-8-e2869-g001){#F1}

RESULTS
=======

Of the 26 articles that were included in the study, we extracted the following data points: type of reconstructive surgery performed (eg, burn, limb, general reconstruction), number of patients in the study, the rates of infection, proportions of superficial versus invasive infection, and would healing outcome. Of 446 articles, only 69 cite the infection rate associated with Integra use, and 43 of these reported no infectious complications. Of the 69 articles, 26 of them reported infections related to the use of Integra.^[@R5],[@R8],[@R13],[@R19]--[@R41]^ When grouping the patient population together from these 26 reports, the generalized incidence of infection is 16.9% out of 1254 Integra sites in 602 patients. The results of the systematic review are summarized in Table [1](#T1){ref-type="table"}.

###### 

Twenty-six Articles That Reported ≥1 Infection with the Use of Integra

  Authors/Year                     Reconstruction Type               Patients (\#)   Sites (\#)   Infections (%)   Superficial (%)   Invasive (%)   Healing Rate (%)
  -------------------------------- --------------------------------- --------------- ------------ ---------------- ----------------- -------------- ------------------
                                   Burns:                                                                                                           
  Heimbach et al^[@R5]^            Burns                             216             758          17.3             13.2              3.1            NR
  Shirley et al^[@R20]^            Burns                             1               1            100              0                 100            0 (death)
  Dantzer and Braye^[@R21]^        Burns                             31              39           12.8             80                20             80
  Groos et al^[@R22]^              Burns                             10              22           22.7             ---               ---            ---
  Lee et al^[@R23]^                Burns                             7               9            11.1             100               0              100
  Bargues et al^[@R24]^            Burns                             50              71           29.6             71.4              28.6           NR
  Yeong et al^[@R25]^              Burns                             10              11           9.1              100               0              100
  Nessler et al^[@R26]^            Pediatric burns                   15              19           21\.             100               0              ---
  Lohana et al^[@R27]^             Burns                             24              37           13.5             100               0              100
  Huang et al^[@R28]^              Burns                             5               5            20               ---               ---            ---
                                   Total                             368             972          18.1                                              
                                   General reconstruction:                                                                                          
  Suzuki et al^[@R29]^             General reconstruction            23              27           3.7              ---               ---            ---
  Suzuki et al^[@R30]^             General reconstruction            41              52           13.4             ---               ---            ---
  Jeschke et al^[@R31]^            General reconstruction            12              12           25               33.3              66.7           NR
  Unglaub et al^[@R32]^            General reconstruction            12              19           5.21             100               0              100
                                   Total                             88              110          10.9                                              NR
                                   Limb reconstruction:                                                                                             
  Bhavsar and Tenenhaus^[@R33]^    Hand reconstruction               4               26           3.8              0                 100            0
  Huemer et al^[@R34]^             Gracilis muscle flap              20              21           9.5              100               0              100
  Todd et al^[@R35]^               Self-harm forearm                 6               6            16.6             100               0              100
  Weigert et al^[@R36]^            Foot and ankle                    21              21           4.7              ---               ---            ---
  Rodriguez Collazo et al^[@R8]^   Limb reconstruction               17              17           23.5             0                 100            75
                                   Total                             68              91           9.8                                               
                                   Pediatric reconstruction:                                                                                        
  Martínez et al^[@R37]^           General reconstruction            11              14           14.2             100               0              100
  Stiefel et al^[@R19]^            General reconstruction            18              18           16.5             ---               ---            ---
  Ghazi and Williams^[@R38]^       General reconstruction            8               8            12.5             100               0              100
  Greenhalgh et al^[@R39]^         Face reconstruction               23              23           17.0             ---               ---            ---
  Casal-Beloy et al^[@R13]^        Hypospadias fistula repair        8               8            12.5             100               0              0
                                   Total                             68              71           15.4                                              NR
                                   Others:                                                                                                          
  Bodmer et al^[@R40]^             Facial reconstruction after SCC   6               6            50               0                 100            0
  Gonzaga et al^[@R41]^            Hidradenitis suppurativa          4               4            25               100               0              0
                                   Total                             10              10           40                                                
  Total patients                   602                                                                                                              
  Total Integra sites              1254                                                                                                             
  Total Integra-site infections    212 (16.9%)                                                                                                      

NR, not reported; SCC, squamous cell carcinoma.

DISCUSSION
==========

Our literature review demonstrated reports of infection associated with the use of Integra in a variety of wound categories. The highest percentage of infection with Integra use was seen in burn reconstructions. This is well supported by the number of articles (Table [1](#T1){ref-type="table"}), including a relatively large study conducted by Heimbach et al,^[@R5]^ which included 13 participating burn centers comprising 216 patients treated with Integra, complicated by infection with an incidence of 16.3% (13.2% superficial and 3.1% invasive). Although the data point to a higher number of infections among the burn reconstruction patient population, patient characteristics, wound pathophysiology, surgeons' technique, and numerous other confounding variables contribute to the observed differences in infection rate among the studies. There was no statistical difference in infection rate among the different categories relative to burn reconstruction. For example, looking at the incidence of infection alone, the *P* value of 2-tailed unpaired *t* test between the burn and non-burn limb reconstruction articles was 0.2316. It is not possible to generate an exact incidence of infection related to Integra use from this review because of the lack of controlled studies and endless confounding variables among the reports. However, Table [1](#T1){ref-type="table"} serves as an organized general overview to the practitioner when discussing with the patient the risks and benefits regarding the use of Integra in wound coverage. Depending on the indications to which Integra is applied, the benefits of its use should routinely surpass its relatively low--moderate rate of infection (13%--15.9%). Most importantly, our literature review identified a single report of a fatal case of toxic shock syndrome related to the use of Integra in burn reconstruction.^[@R20]^

This middle-age patient underwent secondary burn scar revision of neck and axilla with Integra and was readmitted 9 days postoperatively with 2 small (1 cm^2^) areas of nonadherent graft without purulence, but she succumbed from rapid irreversible sepsis. Culture of debrided Integra grew methicillin-resistant *Staphylococcus aureus*.

There are various prophylactic measures that may be taken to prevent the development of infection when using dermal regeneration templates such as Integra. Rigid infection control measures must be exercised, including meticulous wound handling techniques to avoid wound contamination during and after surgery, especially with resistant staphylococcal organisms. Preventive dressing options include nanocrystalline silver products such as Acticoat (silver-coated polyethylene; Smith & Nephew, London, United Kingdom)^[@R42],[@R43]^ and silver-coated polyurethane negative-pressure wound therapy sponge.^[@R44],[@R45]^ Antibiotic prophylaxis may also be used.^[@R13],[@R16]^ The use of these prophylactic measures when employing Integra requires prospective investigation.

CONCLUSIONS
===========

While Integra offers many crucial benefits, such as better chance for revascularization than a direct skin graft in certain situations, the surgeon should be aware that infectious complications are not uncommon. As a result, a careful risk--benefit analysis of its use in reconstruction must be performed, and informed consent openly discussing the risk of infection with the patient is paramount. However rare, acknowledging the possibility of toxic shock syndrome as a complication is crucial in early recognition and expedient life-saving surgical and medical intervention.
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